Genen­tech de­tails claims Sanofi part­ner JHL used stolen trade se­crets to de­vel­op ri­val drugs at an 'as­ton­ish­ing pace'

The feds re­cent­ly round­ed up and charged a group of four, in­clud­ing a long­time se­nior sci­en­tist, with steal­ing trade se­crets from Genen­tech in South San Fran­cis­co. But it’s the com­pa­ny they were al­leged­ly work­ing for — Tai­wan’s JHL Biotech, close­ly part­nered with Sanofi — that has in­spired the big Roche sub­sidiary’s wrath.

In a de­tailed law­suit filed in fed­er­al court, Genen­tech spelled out what it says was a scheme by JHL to steal a march on in­dus­try ri­vals in de­vel­op­ing biosim­i­lars of Rit­ux­an, Her­ceptin and Avastin. And they are af­ter an in­junc­tion to shut it down.

Xan­the Lam

The de­tailed claim sin­gles out Xan­the Lam — a se­nior sci­en­tist with 30 years ex­pe­ri­ence at Genen­tech — and her hus­band, Allen Lam, as prime con­spir­a­tors work­ing for JHL.

Her work at the com­pa­ny touched on many of the block­buster med­i­cines Genen­tech has dis­cov­ered and de­vel­oped. Xan­the’s se­nior role gave her ac­cess to Genen­tech’s se­cure doc­u­ment repos­i­to­ries, and an ar­ray of oth­er files and in­for­ma­tion that Genen­tech keeps se­cret in or­der to pro­tect their val­ue.

In 2013, the suit goes on to claim:

JHL founders Racho Jor­danov and Rose Lin so­licit­ed Xan­the and her hus­band to help JHL de­vel­op biosim­i­lar ver­sions of four Genen­tech med­i­cines: Rit­ux­an, Pul­mozyme, Her­ceptin, and Avastin. Allen Lam agreed to serve as a con­sul­tant for JHL in ex­change for fees as well as founder stock op­tions cor­re­spond­ing to tens of thou­sands of shares in the start­up, and Xan­the be­gan sur­rep­ti­tious­ly work­ing di­rect­ly for JHL, while still serv­ing as Prin­ci­pal Sci­en­tist at Genen­tech.

Ear­ly on in 2013, says the suit, Xan­the told Genen­tech ex­ecs she was go­ing on va­ca­tion for a month, but ac­tu­al­ly went straight to Tai­wan with a Genen­tech lap­top loaded with trade se­crets. Then, in 2017, she’s ac­cused of bring­ing ex-Genen­tech staffer James Quach in­to the con­spir­a­cy, af­ter he had been fired for “per­for­mance-re­lat­ed” is­sues. Through Xan­the, he got in­to Genen­tech’s com­put­er net­work and ob­tained more pro­pri­etary in­fo, the suit al­leges.

And it paid off.

At an as­ton­ish­ing pace for a biotech start­up with few­er than 100 em­ploy­ees, JHL raised mil­lions of dol­lars in pri­vate fund­ing, went pub­lic on the Tai­wan stock ex­change, and man­aged to ob­tain ap­proval from Eu­ro­pean reg­u­la­to­ry au­thor­i­ties to launch a clin­i­cal tri­al of a Rit­ux­an biosim­i­lar in less than four years. By De­cem­ber 2016, JHL had inked a $236 mil­lion deal with French multi­na­tion­al phar­ma­ceu­ti­cal com­pa­ny Sanofi S.A. (“Sanofi”), and the two com­pa­nies are now well on their way to mar­ket­ing JHL’s ver­sion of Rit­ux­an in Chi­na. JHL re­cent­ly an­nounced that it ex­pects to start Phase III tri­als (typ­i­cal­ly the fi­nal stage of clin­i­cal test­ing re­quired to sup­port mar­ket­ing ap­proval) in Eu­rope and in Chi­na dur­ing 2018.

Lawyers for Genen­tech say that Xan­the and her hus­band were al­so linked to four oth­er com­pa­nies in Tai­wan that gained ac­cess to their trade se­crets, which they learned dur­ing a com­pa­ny in­ves­ti­ga­tion of the two. And Xan­the and Quach, they add, will­ing­ly ac­knowl­edged their roles in the af­fair dur­ing in­ter­views with com­pa­ny rep­re­sen­ta­tives.

Each stolen trade se­cret, stand­ing alone, rep­re­sents Genen­tech’s hard work and in­vest­ment, and would aid a com­peti­tor look­ing for a short­cut to de­vel­op­ing and mar­ket­ing its own ri­val med­i­cine. Tak­en to­geth­er as a com­pi­la­tion, the stolen in­for­ma­tion pro­vides a roadmap for JHL to pro­duce biosim­i­lar ver­sions of Genen­tech’s med­i­cines, there­by achiev­ing through theft what Genen­tech ac­com­plished through dili­gence, tri­al-and-er­ror, hard-won know-how, and sig­nif­i­cant in­vest­ment of time and mon­ey. 

The law­suit goes on to al­lege that JHL used the in­for­ma­tion they loot­ed to cre­ate an un­fair ad­van­tage for it­self over Genen­tech, as well as every­one else mak­ing biosim­i­lars of its three big fran­chise drugs. And the com­pa­ny wants the court to is­sue an in­junc­tion that forces JHL to re­turn its trade se­crets, shut­ting down the com­pet­i­tive threat while they seek com­pen­sa­tion for the dam­age done.

Oxitec biologist releases genetically modified mosquitoes in Piracicaba, Brazil in 2016 [credit: Getty Images]

In­trex­on unit push­es back against claims its GM mos­qui­toes are mak­ing dis­ease-friend­ly mu­tants

When the hysteria of Zika transmission sprang into the American zeitgeist a few years ago, UK-based Oxitec was already field-testing its male Aedes aegypti mosquito, crafted to possess a gene engineered to obliterate its progeny long before maturation.

But when a group of independent scientists evaluated the impact of the release of these genetically-modified mosquitoes in a trial conducted by Oxitec in Brazil between 2013 and 2015, they found that some of the offspring had managed to survive — prompting them to speculate what impact the survivors could have on disease transmission and/or insecticide resistance.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

[via AP Images]

Pur­due threat­ens to walk away from set­tle­ment, asks to pay em­ploy­ees mil­lions in bonus­es

There are two updates on the lawsuit against Purdue Pharma over its role in fueling the opioid epidemic, as the Sackler family threatens to walk away from their pledge to pay out $3 billion if a bankruptcy judge does not stop outstanding state lawsuits against them. At the same time, the company has asked permission to pay millions in bonuses to select employees.

Purdue filed for chapter 11 bankruptcy this week as part of its signed resolution to over 2,000 lawsuits. The deal would see the Sackler family that owns Purdue give $3 billion from their personal wealth and the company turned into a trust committed to curbing and reversing overdoses.

Aerial view of Genentech's campus in South San Francisco [Credit: Getty]

Genen­tech sub­mits a plan to near­ly dou­ble its South San Fran­cis­co foot­print

The sign is still there, a quaint reminder of whitewashed concrete not 5 miles from Genentech’s sprawling, chrome-and-glass campus: South Francisco The Industrial City. 

The city keeps the old sign, first erected in 1923, as a tourist site and a kind of civic memento to the days it packed meat, milled lumber and burned enough steel to earn the moniker “Smokestack of the Peninsula.” But the real indication of where you are and how much has changed both in San Francisco and in the global economy since a couple researchers and investors rented out an empty warehouse 40 years ago comes in a far smaller blue sign, resembling a Rotary Club post, off the highway: South San Francisco, The Birthplace of Biotech.

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

IGM Biosciences’ upsized IPO haul, coming after SpringWorks’ sizable public debut, has revved up some momentum for the last rush of biotech IPOs in 2019.

With 39 new listings on the books and roughly two more months to go before winding down, Nasdaq’s head of healthcare listings Jordan Saxe sees the exchange marking 50 to 60 biopharma IPOs for the year.

“December 15 is usually the last possible day that companies will price,” he said, as companies get ready for business talks at the annual JP Morgan Healthcare Conference in January.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.